185 related articles for article (PubMed ID: 37339762)
1. Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.
Salami RK; Valente de Almeida S; Gheorghe A; Njenga S; Silva W; Hauck K
Am J Trop Med Hyg; 2023 Aug; 109(2):228-240. PubMed ID: 37339762
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
[TBL] [Abstract][Full Text] [Related]
4. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.
Jackson KD; Higgins CR; Laing SK; Mwila C; Kobayashi T; Ippolito MM; Sylvia S; Ozawa S
BMC Public Health; 2020 Jul; 20(1):1083. PubMed ID: 32646393
[TBL] [Abstract][Full Text] [Related]
5. Poor-quality antimalarials further health inequities in Uganda.
Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of substandard and falsified antimalarial medications in Nigeria.
Beargie SM; Higgins CR; Evans DR; Laing SK; Erim D; Ozawa S
PLoS One; 2019; 14(8):e0217910. PubMed ID: 31415560
[TBL] [Abstract][Full Text] [Related]
7. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo.
Ozawa S; Haynie DG; Bessias S; Laing SK; Ngamasana EL; Yemeke TT; Evans DR
Am J Trop Med Hyg; 2019 May; 100(5):1149-1157. PubMed ID: 30675851
[TBL] [Abstract][Full Text] [Related]
8. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
9. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
[TBL] [Abstract][Full Text] [Related]
10. Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.
Ozawa S; Higgins CR; Nwokike JI; Phanouvong S
Am J Trop Med Hyg; 2022 Jul; 107(1):14-20. PubMed ID: 35895357
[TBL] [Abstract][Full Text] [Related]
11. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
Petersen A; Held N; Heide L;
PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
[TBL] [Abstract][Full Text] [Related]
13. A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives.
Ahmed J; Modica de Mohac L; Mackey TK; Raimi-Abraham BT
J Med Access; 2022; 6():23992026221074548. PubMed ID: 36204527
[TBL] [Abstract][Full Text] [Related]
14. Global scenario of counterfeit antimalarials: A potential threat.
Arora T; Sharma S
J Vector Borne Dis; 2019; 56(4):288-294. PubMed ID: 33269727
[TBL] [Abstract][Full Text] [Related]
15. Substandard and Falsified Medicines in Myanmar.
Sakuda M; Yoshida N; Takaoka T; Sanada T; Rahman MS; Tanimoto T; Zin T; Kimura K; Tsuboi H
Pharmacy (Basel); 2020 Mar; 8(1):. PubMed ID: 32204459
[No Abstract] [Full Text] [Related]
16. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
Higgins CR; Kobia B; Ozawa S
PLoS One; 2023; 18(1):e0268661. PubMed ID: 36652447
[TBL] [Abstract][Full Text] [Related]
17. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
Mori AT; Meena E; Kaale EA
BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
[TBL] [Abstract][Full Text] [Related]
18. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country.
Khurelbat D; Dorj G; Sunderland B; Sanjjav T; Bayarsaikhan E; Damdinjav D; Dorj G; Jigjidsuren A; Lkhagvasuren O; Erdenetsetseg B
BMC Public Health; 2020 May; 20(1):743. PubMed ID: 32434489
[TBL] [Abstract][Full Text] [Related]
19. Characterizing Medicine Quality by Active Pharmaceutical Ingredient Levels: A Systematic Review and Meta-Analysis across Low- and Middle-Income Countries.
Ozawa S; Chen HH; Lee YA; Higgins CR; Yemeke TT
Am J Trop Med Hyg; 2022 Jun; 106(6):1778-1790. PubMed ID: 35895431
[TBL] [Abstract][Full Text] [Related]
20. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
